Autoantibody testing (by the direct test) and platelet survival study results
| Auto-Ab pattern . | n (%) . | Site of platelet clearance (111In-oxide labeled)* . | |||||
|---|---|---|---|---|---|---|---|
| Nonsplenectomized (37/93 [39.8%]) . | Splenectomized (56/93 [60.2%]) . | ||||||
| Splenic . | Hepatic . | Mixed . | Splenic . | Hepatic . | Mixed . | ||
| Auto-Ab negative | 40 (43%) | 7 | 3 | 4 | 17 | 1 | 8 |
| Auto-Ab positive† | 53 (57%) | 13 | 4 | 6 | 18 | 3 | 9 |
| One positive Ab | 19/53 (36%) | ||||||
| GPIIb-IIIa | 11 | 5 | 0 | 2 | 3 | 1 | 0 |
| GPIb-IX | 4 | 0 | 0 | 0 | 2 | 1 | 1 |
| GPIa-IIa | 4 | 2 | 0 | 0 | 1 | 0 | 1 |
| Two positive Abs | 8/53 (15%) | ||||||
| GPIIb-IIIa and GPIb-IX | 2 | 0 | 0 | 0 | 1 | 0 | 1 |
| GPIIb-IIIa, GPIa-IIa | 6 | 1 | 0 | 0 | 3 | 0 | 2 |
| Three positive Abs | 26/53 (49%) | ||||||
| GPIIb-IIIa, GPIb-IX, and GPIa-IIa | 5 | 4 | 4 | 8 | 1 | 4 | |
| Auto-Ab pattern . | n (%) . | Site of platelet clearance (111In-oxide labeled)* . | |||||
|---|---|---|---|---|---|---|---|
| Nonsplenectomized (37/93 [39.8%]) . | Splenectomized (56/93 [60.2%]) . | ||||||
| Splenic . | Hepatic . | Mixed . | Splenic . | Hepatic . | Mixed . | ||
| Auto-Ab negative | 40 (43%) | 7 | 3 | 4 | 17 | 1 | 8 |
| Auto-Ab positive† | 53 (57%) | 13 | 4 | 6 | 18 | 3 | 9 |
| One positive Ab | 19/53 (36%) | ||||||
| GPIIb-IIIa | 11 | 5 | 0 | 2 | 3 | 1 | 0 |
| GPIb-IX | 4 | 0 | 0 | 0 | 2 | 1 | 1 |
| GPIa-IIa | 4 | 2 | 0 | 0 | 1 | 0 | 1 |
| Two positive Abs | 8/53 (15%) | ||||||
| GPIIb-IIIa and GPIb-IX | 2 | 0 | 0 | 0 | 1 | 0 | 1 |
| GPIIb-IIIa, GPIa-IIa | 6 | 1 | 0 | 0 | 3 | 0 | 2 |
| Three positive Abs | 26/53 (49%) | ||||||
| GPIIb-IIIa, GPIb-IX, and GPIa-IIa | 5 | 4 | 4 | 8 | 1 | 4 | |
Data are from 93 patients (42 males, 54 females).
Ab, antibody; GP, platelet membrane glycoprotein.
Median disease duration at time of PSSs was 13.6 months (range, 0.7-409.8 months).
A total of 14 out of 53 antibody-positive patients (26.4%) also tested positive for autoantibodies by the indirect test.